La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

Identifieur interne : 003303 ( Main/Merge ); précédent : 003302; suivant : 003304

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

Auteurs : Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni]

Source :

RBID : Pascal:03-0498653

Descripteurs français

English descriptors

Abstract

Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using 18F-dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-terminal function in de novo patients with clinical and 18F-dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen 18F-dopa uptake (Ki) between baseline and 2-year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region-of-interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (-13.4%; n = 68) compared with levodopa (-20.3%; n = 59; 95% confidence interval [CI], 0.65-13.06). Statistical parametric mapping localized lesser reductions in 18F-dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, -14.1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by 18F-dopa PET.

Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:03-0498653

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study</title>
<author>
<name sortKey="Whone, Alan L" sort="Whone, Alan L" uniqKey="Whone A" first="Alan L." last="Whone">Alan L. Whone</name>
<affiliation wicri:level="3">
<inist:fA14 i1="01">
<s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Atlanta, GA</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Davis, Margaret" sort="Davis, Margaret" uniqKey="Davis M" first="Margaret" last="Davis">Margaret Davis</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Atlanta, GA</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Reske, Sven" sort="Reske, Sven" uniqKey="Reske S" first="Sven" last="Reske">Sven Reske</name>
<affiliation wicri:level="4">
<inist:fA14 i1="04">
<s1>Universität Ulm</s1>
<s2>Ulm</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName>
<region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Ulm</settlement>
<settlement type="city">Ulm</settlement>
</placeName>
<orgName type="university">Université d'Ulm</orgName>
</affiliation>
</author>
<author>
<name sortKey="Nahmias, Claude" sort="Nahmias, Claude" uniqKey="Nahmias C" first="Claude" last="Nahmias">Claude Nahmias</name>
<affiliation wicri:level="4">
<inist:fA14 i1="05">
<s1>McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université McMaster</orgName>
</affiliation>
</author>
<author>
<name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="4">
<inist:fA14 i1="06">
<s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Ontario, Canada</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="3">
<inist:fA14 i1="07">
<s1>Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Ribeiro, Maria J" sort="Ribeiro, Maria J" uniqKey="Ribeiro M" first="Maria J." last="Ribeiro">Maria J. Ribeiro</name>
<affiliation wicri:level="3">
<inist:fA14 i1="08">
<s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName>
<settlement type="city">Orsay</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name>
<affiliation wicri:level="3">
<inist:fA14 i1="08">
<s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName>
<settlement type="city">Orsay</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1">
<inist:fA14 i1="09">
<s1>Department of Clinical Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName>
<settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1">
<inist:fA14 i1="10">
<s1>University of South Florida and Tampa General Healthcare</s1>
<s2>Tampa, FL</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of South Florida and Tampa General Healthcare</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation wicri:level="3">
<inist:fA14 i1="01">
<s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">03-0498653</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0498653 INIST</idno>
<idno type="RBID">Pascal:03-0498653</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A43</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000280</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000917</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000917</idno>
<idno type="wicri:doubleKey">0364-5134:2003:Whone A:slower:progression:of</idno>
<idno type="wicri:Area/Main/Merge">003303</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study</title>
<author>
<name sortKey="Whone, Alan L" sort="Whone, Alan L" uniqKey="Whone A" first="Alan L." last="Whone">Alan L. Whone</name>
<affiliation wicri:level="3">
<inist:fA14 i1="01">
<s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Atlanta, GA</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of British Columbia</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Davis, Margaret" sort="Davis, Margaret" uniqKey="Davis M" first="Margaret" last="Davis">Margaret Davis</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Atlanta, GA</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Reske, Sven" sort="Reske, Sven" uniqKey="Reske S" first="Sven" last="Reske">Sven Reske</name>
<affiliation wicri:level="4">
<inist:fA14 i1="04">
<s1>Universität Ulm</s1>
<s2>Ulm</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName>
<region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Tübingen</region>
<settlement type="city">Ulm</settlement>
<settlement type="city">Ulm</settlement>
</placeName>
<orgName type="university">Université d'Ulm</orgName>
</affiliation>
</author>
<author>
<name sortKey="Nahmias, Claude" sort="Nahmias, Claude" uniqKey="Nahmias C" first="Claude" last="Nahmias">Claude Nahmias</name>
<affiliation wicri:level="4">
<inist:fA14 i1="05">
<s1>McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Hamilton (Ontario)</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université McMaster</orgName>
</affiliation>
</author>
<author>
<name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="4">
<inist:fA14 i1="06">
<s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Ontario, Canada</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="3">
<inist:fA14 i1="07">
<s1>Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName>
<region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Ribeiro, Maria J" sort="Ribeiro, Maria J" uniqKey="Ribeiro M" first="Maria J." last="Ribeiro">Maria J. Ribeiro</name>
<affiliation wicri:level="3">
<inist:fA14 i1="08">
<s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName>
<settlement type="city">Orsay</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name>
<affiliation wicri:level="3">
<inist:fA14 i1="08">
<s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName>
<settlement type="city">Orsay</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1">
<inist:fA14 i1="09">
<s1>Department of Clinical Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName>
<settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1">
<inist:fA14 i1="10">
<s1>University of South Florida and Tampa General Healthcare</s1>
<s2>Tampa, FL</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of South Florida and Tampa General Healthcare</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation wicri:level="3">
<inist:fA14 i1="01">
<s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
<imprint>
<date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Agonist</term>
<term>Aminoacid</term>
<term>Cartography</term>
<term>Catecholamine</term>
<term>Comparative study</term>
<term>D2 Dopamine receptor</term>
<term>Dopa</term>
<term>Dopamine</term>
<term>Dopamine agonist</term>
<term>Double blind study</term>
<term>Emission tomography</term>
<term>Human</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Positron</term>
<term>Prognosis</term>
<term>Putamen</term>
<term>Ropinirole</term>
<term>Uptake</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Parkinson maladie</term>
<term>Ropinirole</term>
<term>Tomoscintigraphie</term>
<term>Dopa</term>
<term>Dopamine</term>
<term>Putamen</term>
<term>Cartographie</term>
<term>Etude comparative</term>
<term>Lévodopa</term>
<term>Positon</term>
<term>Stimulant dopaminergique</term>
<term>Etude double insu</term>
<term>Homme</term>
<term>Pronostic</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Aminoacide</term>
<term>Catécholamine</term>
<term>Captation</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Cartographie</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using
<sup>18</sup>
F-dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-terminal function in de novo patients with clinical and
<sup>18</sup>
F-dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen
<sup>18</sup>
F-dopa uptake (Ki) between baseline and 2-year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region-of-interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (-13.4%; n = 68) compared with levodopa (-20.3%; n = 59; 95% confidence interval [CI], 0.65-13.06). Statistical parametric mapping localized lesser reductions in
<sup>18</sup>
F-dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, -14.1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by
<sup>18</sup>
F-dopa PET.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Allemagne</li>
<li>Autriche</li>
<li>Canada</li>
<li>France</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region>
<li>Angleterre</li>
<li>Bade-Wurtemberg</li>
<li>District de Tübingen</li>
<li>Grand Londres</li>
<li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
<li>Ontario</li>
<li>Tyrol (Land)</li>
</region>
<settlement>
<li>Hamilton (Ontario)</li>
<li>Innsbruck</li>
<li>Londres</li>
<li>Orsay</li>
<li>Toronto</li>
<li>Toulouse</li>
<li>Ulm</li>
</settlement>
<orgName>
<li>Université McMaster</li>
<li>Université d'Ulm</li>
<li>Université de Toronto</li>
<li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree>
<country name="Royaume-Uni">
<region name="Angleterre">
<name sortKey="Whone, Alan L" sort="Whone, Alan L" uniqKey="Whone A" first="Alan L." last="Whone">Alan L. Whone</name>
</region>
<name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
</country>
<country name="États-Unis">
<noRegion>
<name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
</noRegion>
<name sortKey="Davis, Margaret" sort="Davis, Margaret" uniqKey="Davis M" first="Margaret" last="Davis">Margaret Davis</name>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</country>
<country name="Canada">
<noRegion>
<name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
</noRegion>
<name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<name sortKey="Nahmias, Claude" sort="Nahmias, Claude" uniqKey="Nahmias C" first="Claude" last="Nahmias">Claude Nahmias</name>
</country>
<country name="Allemagne">
<region name="Bade-Wurtemberg">
<name sortKey="Reske, Sven" sort="Reske, Sven" uniqKey="Reske S" first="Sven" last="Reske">Sven Reske</name>
</region>
</country>
<country name="France">
<region name="Occitanie (région administrative)">
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</region>
<name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name>
<name sortKey="Ribeiro, Maria J" sort="Ribeiro, Maria J" uniqKey="Ribeiro M" first="Maria J." last="Ribeiro">Maria J. Ribeiro</name>
</country>
<country name="Autriche">
<region name="Tyrol (Land)">
<name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner Poewe</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003303 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003303 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:03-0498653
   |texte=   Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022